ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1.
World Health Organization, 1981. Synopsis of the world malaria situation in 1979. Wkly Epidemiol Rec 56: 145–149.
-
2.
Chai IH, Lim GI, Yoon SN, Oh WI, Kim SJ, Chai JY, 1994. Occurrence of tertian malaria in a male patient who has never been abroad. Korean J Parasitol 32: 195–200.
-
3.
Park JW, Klein TA, Lee HC, Pacha LA, Ryu SH, Yeom JS, Moon SH, Kim TS, Chai JY, Oh MD, Choe KW, 2003. Vivax malaria: a continuing health threat to the Republic of Korea. Am J Trop Med Hyg 69: 159–167.
-
4.
Yeom JS, Ryu SH, Oh S, Lee WJ, Kim TS, Kim KH, Kim YA, Ahn SY, Cha JE, Park JW, 2005. Status of Plasmodium vivax malaria in the Republic of Korea during 2001–2003. Am J Trop Med Hyg 73: 604–608.
-
5.
Brega S, Meslin B, de Monbrison F, Severini C, Gradoni L, Udomsangpetch R, Sutanto I, Peyron F, Picot S, 2005. Identification of the Plasmodium vivax mdr-like gene (pvmdr1) and analysis of single-nucleotide polymorphisms among isolates from different areas of endemicity. J Infect Dis 191: 272–277.
-
6.
Suwanarusk R, Russell B, Chavchich M, Chalfein F, Kenangalem E, Kosaisavee V, Prasetyorini B, Piera KA, Barends M, Brockman A, Lek-Uthai U, Anstey NM, Tjitra E, Nosten F, Cheng Q, Price RN, 2007. Chloroquine resistant Plasmodium vivax: in vitro characterisation and association with molecular polymorphisms. PLoS One 31: e1089.
-
7.
World Health Organization, 2003. Monitoring Antimalarial Drug Resistance: A Report of a Consultation. Geneva, Switzerland: World Health Organization.
-
8.
Contacos PG, Collins WE, Jeffery GM, Krotoski WA, Howard WA, 1972. Studies on the characterization of Plasmodium vivax strains from Central America. Am J Trop Med Hyg 21: 707–712.
-
9.
Yeom JS, Ryu SH, Oh S, Choi DH, Song KJ, Oh YH, Lee JH, Kim YA, Ahn SY, Yang HY, Cha JE, Park JW, 2005. Evaluation of anti-malarial effects of mass chemoprophylaxis in the Republic of Korea army. J Korean Med Sci 20: 707–712.
-
10.
Park K, Kang JK, 2003. Effectiveness of primaquine terminal prophylaxis against late primary attacks of Plasmodium vivax malaria: a case-control study among troops of the Republic of Korea army. Trans R Soc Trop Med Hyg 97: 441–442.
-
11.
Rombo L, Berqvist Y, Hellgren U, 1987. Chloroquine and desethychloroquine concentrations during regular long-term malaria prophylaxis. Bull World Health Organ 65: 879–883.
-
12.
Baird JK, 2004. Chloroquine resistance in Plasmodium vivax. Antimicrob Agents Chemother 48: 4074–4083.
-
13.
Lee SW, Lee M, Lee DD, Kim C, Kim YJ, Kim JY, Green MD, Klein TA, Kim HC, Nettey H, Ko DH, Kim H, Park I, 2009. Biological resistance of hydroxychloroquine for Plasmodium vivax malaria in the Republic of Korea. Am J Trop Med Hyg 81: 600–604.
-
14.
Peel SA, 2001. The ABC transporter genes of Plasmodium falciparum and drug resistance. Drug Resist Updat 4: 66–74.
-
15.
Picot S, Brega S, Gérôme P, Velut G, de Monbrison F, Cheminel V, Peyron F, 2005. Absence of nucleotide polymorphism in a Plasmodium vivax multidrug resistance gene after failure of mefloquine prophylaxis in French Guyana. Trans R Soc Trop Med Hyg 99: 234–237.
-
16.
Sá JM, Nomura T, Neves J, Baird JK, Wellems TE, del Portillo HA, 2005. Plasmodium vivax: allele variants of the mdr1 gene do not associate with chloroquine resistance among isolates from Brazil, Papua, and monkey-adapted strains. Exp Parasitol 109: 256–259.
-
17.
Suwanarusk R, Chavchich M, Russell B, Jaidee A, Chalfein F, Barends M, Prasetyorini B, Kenangalem E, Piera KA, Lek-Uthai U, Anstey NM, Tjitra E, Nosten F, Cheng Q, Price RN, 2008. Amplification of pvmdr1 associated with multidrug-resistant Plasmodium vivax. J Infect Dis 198: 1558–1564.
-
18.
Baird JK, Hoffman SL, 2004. Primaquine therapy for malaria. Clin Infect Dis 39: 1336–1345.
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 150 | 125 | 10 |
| Full Text Views | 279 | 13 | 1 |
| PDF Downloads | 60 | 7 | 1 |
Therapeutic Efficacy of Chloroquine in Plasmodium vivax and the pvmdr1 Polymorphisms in the Republic of Korea Under Mass Chemoprophylaxis
Young Keun Kim
Young Keun Kim
Department of Internal Medicine, Yonsei University, Wonju College of Medicine, Wonju, Korea; Konyang University, Myunggok Medical Research Institute, Daejeon, Korea; Department of Preventive Medicine, Yonsei University College of Medicine, Seoul, Korea; Department of Preventive Medicine, The Armed Forces Medical Command, Sungnam, Korea; Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea
Search for other papers by Young Keun Kim in
Current site
Google Scholar
PubMed
Search for other papers by Young Keun Kim in
Current site
Google Scholar
PubMed
Changsoo Kim
Changsoo Kim
Department of Internal Medicine, Yonsei University, Wonju College of Medicine, Wonju, Korea; Konyang University, Myunggok Medical Research Institute, Daejeon, Korea; Department of Preventive Medicine, Yonsei University College of Medicine, Seoul, Korea; Department of Preventive Medicine, The Armed Forces Medical Command, Sungnam, Korea; Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea
Search for other papers by Changsoo Kim in
Current site
Google Scholar
PubMed
Search for other papers by Changsoo Kim in
Current site
Google Scholar
PubMed
Inho Park
Inho Park
Department of Internal Medicine, Yonsei University, Wonju College of Medicine, Wonju, Korea; Konyang University, Myunggok Medical Research Institute, Daejeon, Korea; Department of Preventive Medicine, Yonsei University College of Medicine, Seoul, Korea; Department of Preventive Medicine, The Armed Forces Medical Command, Sungnam, Korea; Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea
Search for other papers by Inho Park in
Current site
Google Scholar
PubMed
Search for other papers by Inho Park in
Current site
Google Scholar
PubMed
Hyo Youl Kim
Hyo Youl Kim
Department of Internal Medicine, Yonsei University, Wonju College of Medicine, Wonju, Korea; Konyang University, Myunggok Medical Research Institute, Daejeon, Korea; Department of Preventive Medicine, Yonsei University College of Medicine, Seoul, Korea; Department of Preventive Medicine, The Armed Forces Medical Command, Sungnam, Korea; Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea
Search for other papers by Hyo Youl Kim in
Current site
Google Scholar
PubMed
Search for other papers by Hyo Youl Kim in
Current site
Google Scholar
PubMed
Jun Yong Choi
Jun Yong Choi
Department of Internal Medicine, Yonsei University, Wonju College of Medicine, Wonju, Korea; Konyang University, Myunggok Medical Research Institute, Daejeon, Korea; Department of Preventive Medicine, Yonsei University College of Medicine, Seoul, Korea; Department of Preventive Medicine, The Armed Forces Medical Command, Sungnam, Korea; Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea
Search for other papers by Jun Yong Choi in
Current site
Google Scholar
PubMed
Search for other papers by Jun Yong Choi in
Current site
Google Scholar
PubMed
June Myung Kim
June Myung Kim
Department of Internal Medicine, Yonsei University, Wonju College of Medicine, Wonju, Korea; Konyang University, Myunggok Medical Research Institute, Daejeon, Korea; Department of Preventive Medicine, Yonsei University College of Medicine, Seoul, Korea; Department of Preventive Medicine, The Armed Forces Medical Command, Sungnam, Korea; Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea
Search for other papers by June Myung Kim in
Current site
Google Scholar
PubMed
Search for other papers by June Myung Kim in
Current site
Google Scholar
PubMed
Chemoprophylaxis with hydroxychloroquine (HCQ) and primaquine has been used in the Republic of Korea (ROK) Army since 1997. It may facilitate the development of chloroquine (CQ)-resistant strains of Plasmodium vivax. We investigated the therapeutic efficacy of HCQ and the pvmdr1 gene polymorphisms in P. vivax. From June to September 2006, 102 soldiers with vivax malaria near the demilitarized zone in Gyeonggi-do, ROK, were enrolled in the study. We determined the status of compliance of chemoprophylaxis. In 85 patients, therapeutic efficacy was monitored 28 days after standard HCQ treatment; 66 (64.7%) of 102 malaria patients had taken all chemoprolaxis with HCQ. In all patients enrolled in the therapeutic efficacy monitoring, parasitemia had not been observed since 3 days after standard HCQ treatment. However, the ubiquitous presence of the F1076L mutation of the pvmdr1 was observed. There was no evidence that the F1076L mutation of pvmdr1 could contribute to failure of HCQ treatment.
Author Notes
Financial support: This work was supported in part by Konyang University Myung Gok Research Fund of 2007.
Authors' addresses: Young Keun Kim, Department of Internal Medicine, Yonsei University, Wonju College of Medicine, Kangwon-do, Republic of Korea, E-mail: amoxj@yonsei.ac.kr. Changsoo Kim, Department of Preventive Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea, E-mail: preman@yuhs.ac. Inho Park, Chief of Professional Service, Armed Forces Seoul Hospital, Seoul, Republic of Korea, E-mail: park_in_ho@yahoo.co.kr. Hyo Youl Kim, Yonsei University, Wonju College of Medicine, Kangwon-do, Republic of Korea, E-mail: hyksos@yonsei.ac.kr. Jun Yong Choi and June Myung Kim, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea, E-mails: seran@yuhs.ac and jmkim@yuhs.ac.
ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1.
World Health Organization, 1981. Synopsis of the world malaria situation in 1979. Wkly Epidemiol Rec 56: 145–149.
-
2.
Chai IH, Lim GI, Yoon SN, Oh WI, Kim SJ, Chai JY, 1994. Occurrence of tertian malaria in a male patient who has never been abroad. Korean J Parasitol 32: 195–200.
-
3.
Park JW, Klein TA, Lee HC, Pacha LA, Ryu SH, Yeom JS, Moon SH, Kim TS, Chai JY, Oh MD, Choe KW, 2003. Vivax malaria: a continuing health threat to the Republic of Korea. Am J Trop Med Hyg 69: 159–167.
-
4.
Yeom JS, Ryu SH, Oh S, Lee WJ, Kim TS, Kim KH, Kim YA, Ahn SY, Cha JE, Park JW, 2005. Status of Plasmodium vivax malaria in the Republic of Korea during 2001–2003. Am J Trop Med Hyg 73: 604–608.
-
5.
Brega S, Meslin B, de Monbrison F, Severini C, Gradoni L, Udomsangpetch R, Sutanto I, Peyron F, Picot S, 2005. Identification of the Plasmodium vivax mdr-like gene (pvmdr1) and analysis of single-nucleotide polymorphisms among isolates from different areas of endemicity. J Infect Dis 191: 272–277.
-
6.
Suwanarusk R, Russell B, Chavchich M, Chalfein F, Kenangalem E, Kosaisavee V, Prasetyorini B, Piera KA, Barends M, Brockman A, Lek-Uthai U, Anstey NM, Tjitra E, Nosten F, Cheng Q, Price RN, 2007. Chloroquine resistant Plasmodium vivax: in vitro characterisation and association with molecular polymorphisms. PLoS One 31: e1089.
-
7.
World Health Organization, 2003. Monitoring Antimalarial Drug Resistance: A Report of a Consultation. Geneva, Switzerland: World Health Organization.
-
8.
Contacos PG, Collins WE, Jeffery GM, Krotoski WA, Howard WA, 1972. Studies on the characterization of Plasmodium vivax strains from Central America. Am J Trop Med Hyg 21: 707–712.
-
9.
Yeom JS, Ryu SH, Oh S, Choi DH, Song KJ, Oh YH, Lee JH, Kim YA, Ahn SY, Yang HY, Cha JE, Park JW, 2005. Evaluation of anti-malarial effects of mass chemoprophylaxis in the Republic of Korea army. J Korean Med Sci 20: 707–712.
-
10.
Park K, Kang JK, 2003. Effectiveness of primaquine terminal prophylaxis against late primary attacks of Plasmodium vivax malaria: a case-control study among troops of the Republic of Korea army. Trans R Soc Trop Med Hyg 97: 441–442.
-
11.
Rombo L, Berqvist Y, Hellgren U, 1987. Chloroquine and desethychloroquine concentrations during regular long-term malaria prophylaxis. Bull World Health Organ 65: 879–883.
-
12.
Baird JK, 2004. Chloroquine resistance in Plasmodium vivax. Antimicrob Agents Chemother 48: 4074–4083.
-
13.
Lee SW, Lee M, Lee DD, Kim C, Kim YJ, Kim JY, Green MD, Klein TA, Kim HC, Nettey H, Ko DH, Kim H, Park I, 2009. Biological resistance of hydroxychloroquine for Plasmodium vivax malaria in the Republic of Korea. Am J Trop Med Hyg 81: 600–604.
-
14.
Peel SA, 2001. The ABC transporter genes of Plasmodium falciparum and drug resistance. Drug Resist Updat 4: 66–74.
-
15.
Picot S, Brega S, Gérôme P, Velut G, de Monbrison F, Cheminel V, Peyron F, 2005. Absence of nucleotide polymorphism in a Plasmodium vivax multidrug resistance gene after failure of mefloquine prophylaxis in French Guyana. Trans R Soc Trop Med Hyg 99: 234–237.
-
16.
Sá JM, Nomura T, Neves J, Baird JK, Wellems TE, del Portillo HA, 2005. Plasmodium vivax: allele variants of the mdr1 gene do not associate with chloroquine resistance among isolates from Brazil, Papua, and monkey-adapted strains. Exp Parasitol 109: 256–259.
-
17.
Suwanarusk R, Chavchich M, Russell B, Jaidee A, Chalfein F, Barends M, Prasetyorini B, Kenangalem E, Piera KA, Lek-Uthai U, Anstey NM, Tjitra E, Nosten F, Cheng Q, Price RN, 2008. Amplification of pvmdr1 associated with multidrug-resistant Plasmodium vivax. J Infect Dis 198: 1558–1564.
-
18.
Baird JK, Hoffman SL, 2004. Primaquine therapy for malaria. Clin Infect Dis 39: 1336–1345.
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 150 | 125 | 10 |
| Full Text Views | 279 | 13 | 1 |
| PDF Downloads | 60 | 7 | 1 |